Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 53-66

  Gussio, Rick ^a   Zaharevitz, Daniel W ^a   McGrath, Connor F ^a   Pattabiraman, Nagarajan ^b   Kellogg, Glen E ^c   Schultz, Christiane ^d   Link, Andreas ^d   Kunick, Conrad ^d   Leost, Maryse ^e   Meijer, Laurent ^e   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF HAMBURG   (Germany)

^e STATION BIOLOGIQUE   (France)

Author keywords

3 D QSAR; Cyclin dependent kinase inhibitors; Paullones; Protein homology modeling; Quantum mechanical calculations; Structure based drug design

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR; LIGAND;

ARTICLE; HYDROGEN BOND; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM MECHANICS;

EID: 0034089542     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abraham D.J., Kellogg G.E., Holt J.M., Ackers G.K. (1997) Hydropathic analysis of the non-covalent interactions between molecular subunits of structurally characterized hemoglobins. Journal of Molecular Biology, 212, 613.
2. Becke A.D. (1993) Density-functional thermochemistry. III. The role of exact exchange. Journal of Chemical Physics, 98, 5648.
3. Chang Y.T., Gray N.G., Rosania G.R., Sutherlin D.P., Kwon S., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. (1999) Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chemistry & Biology, 6, 361.
4. De Azevedo W.F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S.H. (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. European Journal of Biochemistry, 243, 518.
5. Garrett M.D., Fattaey A. (1999) CDK inhibition and cancer therapy. Current Opinion in Genetics & Development, 9, 104.
6. Glauser W.A., Raber D.J., Stevens B. (1989) Electron donoracceptor complexes. 2. Evaluation of the criteria for ground-state stability of weak bp-ap complexes using semiempirical energy surfaces. Journal of Physical Chemistry, 93, 1784.
7. Godbout N., Salahub J., Andzelm E., Wimmer E. (1992) Optimization of Gaussian-type basis sets for local spin density functional calculations. Part I. Boron through neon, optimization technique and validation. Canadian Journal of Chemistry, 70, 560.
8. Gray N.S., Wodicka L., Thunnissen A.M., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.H., Lockhart D.J., Schultz PG. (1998) Exploiting chemical libraries, structure, and genomics in the search of kinase inhibitors. Science, 281, 533.
9. Gray N., Detivaud L., Doerig C., Meijer L. (1999) ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry, 6, 859.
10. Hoessel R., Leclerc S., Endicott J., Noble M., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology, 1, 60.
11. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H. (1994) A cell cycle regulator potentially involved in genesis of may tumor-types. Science, 264, 436.
12. Kellogg G.E., Scarsdale J.N., Fornari F.A. Jr (1998) Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double stranded polynucleotides. Nucleic Acids Research, 26, 4721.
13. Lee C., Yang W., Parr R.G. (1988) Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Physical Review B, 37, 785.
14. Levine A.J. (1997) The cellular gatekeeper for growth and division. Cell, 88, 323.
15. Maple J.R., Thacher T.S., Dinur U., Hagler A.T. (1990) Biosym force field research results in new technique for the extraction of inter- and intramolecular forces. Chemistry, Design and Automation News, 5, 5.
16. Meijer L. (1995) Chemical inhibitors of cyclin-dependent kinases. In Progress in Cell Cycle Research. Meijer L., Guidet S., Tung H.Y.L. (eds), vol. 1, p. 351. Plenum Press: New York.
17. Meijer L. (1996) Chemical inhibitors of cyclin-dependent kinases. Trends in Cellular Biology, 6, 393.
18. Meijer L., Kim S.H. (1997) Chemical inhibitors of cyclin-dependent kinases. Methods in Enzymology, 283, 113.
19. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of cyclin-dependent kinases cdc2, cdk2, and cdk5. European Journal of Biochemistry, 243, 527.
20. Morgan D. (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annual Review in Cellular Developmental Biology, 13, 261.
21. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carlson D.A. (1994) Deletions of the cylin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753.
22. Parr R.G., Yang W. (1989) In Density Functional Theory of Atoms and Molecules. Oxford University Press: New York.
23. Paull K.D., Hamel E., Malspeis L. (1995) Prediction of biochemical mechanism cf action from the in vitro antitumor screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents. Foye W.O. (ed.). American Chemical Society Books: Washington, DC.
24. Pavletich N.P. (1999) Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. Journal of Molecular Biology, 287, 821.
25. Ricca A., Bauschlicher C.W. (1995) A comparison of density functional theory with ab initio approaches for systems involving first transition row metals. Theoretica Chimica Acta, 92, 123.
26. Russo A.A., Jeffrey P.D., Patten A.K., Massague J., Pavletich N.P. (1996a) Crystal structure of the p27Kip1 cyclin-dependent kinase inhibitor bound to the cylin A-Cdk2 complex. Nature, 382, 325.
27. Russo A.A., Jeffrey P.D., Pavletich N.P. (1996b) Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Structural Biology, 3, 696.
28. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., Kunick C. (1999) Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. Journal of Medicinal Chemistry, 42, 2909.
29. Sedlacek H.H., Czech J., Naik R., Kaur G., Worland P., Losiewicz M., Parker B., Carlson B., Smith A., Senderowicz A., Sausville E. (1996) Flavopiridol (L86-8275, NSC-649850), a new kinase inhibitor for tumor therapy. International Journal of Oncology, 9, 1143.
30. Senderowicz A.M., Headlee D., Stinson S.F., Lush R.M., Kalil N., Villalba L., Hill K., Steinberg S.M., Figg W.D., Tompkins A., Arbuck S.G., Sausville E.A. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor. Journal of Clinical Oncology, 16, 2986.
31. Serrano M., Hannon G.J., Beach D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704.
32. Sherr C.J., Roberts J.M. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases.Genes and Development, 1149.
33. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., Leclerc S. (1994) Inhibition of cyclin-dependent kinases by purine analogues. European Journal Biochemistry. 224, 771.
34. Vosko S.J., Wilk L., Nusair M. (1980) Accurate spin-dependent electron liquid correlation energies for local spin density calculations. Canadian Journal of Physics, 58, 1200.
35. Wada M., Hosotani R., Lee J.U., Doi R., Koshiba T., Fujimoto K., Miyamoto Y., Tsuji S., Nakajima S., Okuyama A. (1998) An exogenous cdk inhibitor, butyro-lactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Research, 18, 2559.
36. Yamamoto H., Monden T., Miyoshi H., Izawa H., Ikeda K., Tsujie M., Ohnishi T., Sekimoto M., Tomita N., Monden M. (1998) Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. International Journal of Oncology, 13, 233.
37. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., Sausville E.A. (1999) Discovery and initial characterization of the paullones, a novel class of small molecule inhibitors of cylin-dependent kinases. Cancer Research, 59, 2566.
38. Ziegler T., Tschinke V. (1991) Density functional theory as a practical tool in organometallic energetics and dynamics. In Density Functional Methods in Chemistry. Labanowski J., Andzelm J. (eds), p. 39. Springer Verlag: New York.